[{"data":1,"prerenderedAt":117},["ShallowReactive",2],{"guidelines-page":3,"guideline-cats":78},{"code":4,"msg":5,"rows":6,"pageNum":13,"pageSize":74,"total":68,"hasNext":75,"success":76,"time":77},200,"操作成功",[7,21,31,42,53,63],{"version":8,"nameZh":9,"fileUrlZh":10,"code":11,"fileUrlEn":12,"guidelineId":13,"externalUrl":10,"nameEn":14,"logoUrl":10,"studyType":15,"releaseState":16,"summaryZh":17,"sortNum":18,"summaryEn":19,"status":20},"2010 修订 · 6 领域 \u002F 17 条目","STRICTA（针刺临床试验干预措施报告标准）","","STRICTA","https:\u002F\u002Faction-gmu.oss-cn-guangzhou.aliyuncs.com\u002Fsite\u002Fguideline\u002F6cdbc5f6f07b41b88e21c4b75a6713cc.pdf",1,"STRICTA (Standards for Reporting Interventions in Clinical Trials of Acupuncture)","rct","open","STRICTA（针刺临床试验干预措施报告标准）是 CONSORT 的官方扩展，规定 RCT 中针刺干预应如何报告：针刺理论依据、针刺细节（选穴、深度、得气反应）、治疗方案、联合干预、施术者背景，以及对照\u002F对照措施的设置。",0,"STRICTA (Standards for Reporting Interventions in Clinical Trials of Acupuncture) is a CONSORT extension. It specifies how acupuncture interventions should be reported in RCTs: acupuncture rationale, needling details (points, depth, response sought), treatment regimen, co-interventions, practitioner background and control\u002Fcomparator.","0",{"version":22,"nameZh":23,"fileUrlZh":10,"code":24,"fileUrlEn":25,"guidelineId":26,"externalUrl":10,"nameEn":27,"logoUrl":10,"studyType":28,"releaseState":16,"summaryZh":29,"sortNum":13,"summaryEn":30,"status":20},"2018 扩展版","SPIRIT-TCM Extension 2018（中医药临床试验方案标准条目）","SPIRIT","https:\u002F\u002Faction-gmu.oss-cn-guangzhou.aliyuncs.com\u002Fsite\u002Fguideline\u002F28ecbba4284343659802d920cd42415b.pdf",2,"SPIRIT-TCM Extension 2018","protocol","SPIRIT-TCM Extension 2018 在 SPIRIT 声明（干预性试验方案标准条目）基础上针对中医药（含针刺）适配，规定试验方案在开始前需预先明确的内容，使计划中的方法在实施前即透明可核。","The SPIRIT-TCM Extension 2018 adapts the SPIRIT statement (Standard Protocol Items: Recommendations for Interventional Trials) for traditional Chinese medicine, including acupuncture. It guides what a trial protocol must pre-specify, so the planned methods are transparent before the trial begins.",{"version":32,"nameZh":33,"fileUrlZh":10,"code":34,"fileUrlEn":35,"guidelineId":36,"externalUrl":10,"nameEn":37,"logoUrl":38,"studyType":39,"releaseState":16,"summaryZh":40,"sortNum":26,"summaryEn":41,"status":20},"现行清单","PRISMA for Acupuncture（针刺系统综述与 Meta 分析报告规范）","PRISMA","https:\u002F\u002Faction-gmu.oss-cn-guangzhou.aliyuncs.com\u002Fsite\u002Fguideline\u002F9c57f7310f4f4d20b50b6fc4fb7ca119.pdf",3,"PRISMA for Acupuncture","\u002Fassets\u002Flogo-prisma.png","sr","PRISMA for Acupuncture 为综合针刺证据的系统综述与 Meta 分析提供报告条目，重点回应证据合成中如何处理针刺特有属性（干预细节、辨证分型、假针\u002F安慰对照等）。","PRISMA for Acupuncture provides reporting items for systematic reviews and meta-analyses that synthesise acupuncture evidence, addressing how acupuncture-specific characteristics (intervention details, syndrome differentiation, sham\u002Fplacebo controls) should be handled in evidence synthesis.",{"version":43,"nameZh":44,"fileUrlZh":10,"code":45,"fileUrlEn":46,"guidelineId":47,"externalUrl":10,"nameEn":48,"logoUrl":49,"studyType":50,"releaseState":16,"summaryZh":51,"sortNum":36,"summaryEn":52,"status":20},"v1.0 · 13 领域 \u002F 30 条目","CARE for Acupuncture（针刺病例报告规范）","CARE","https:\u002F\u002Faction-gmu.oss-cn-guangzhou.aliyuncs.com\u002Fsite\u002Fguideline\u002F818548cb76424459a92ca1d51b69c136.pdf",4,"CARE for Acupuncture","\u002Fassets\u002Flogo-care.png","case","CARE for Acupuncture 将 CARE（病例报告）声明扩展至针刺病例报告与病例系列。它依循 EQUATOR 方法学、由国际多学科专家组制定，补齐了通用病例报告规范所缺失的针刺细节：针具类型、选穴与操作、辨证分型、得气与不良事件。","CARE for Acupuncture extends the CARE (CAse REport) statement to acupuncture case reports and case series. Developed under the EQUATOR methodology by an international, multidisciplinary panel, it adds the acupuncture-specific detail that generic case-report guidance omits — needle type, point selection and operation, syndrome differentiation, de qi, and adverse events.",{"version":54,"nameZh":55,"fileUrlZh":10,"code":56,"fileUrlEn":57,"guidelineId":58,"externalUrl":10,"nameEn":59,"logoUrl":10,"studyType":60,"releaseState":16,"summaryZh":61,"sortNum":47,"summaryEn":62,"status":20},"现行版","RIGHT for Acupuncture（针刺临床实践指南报告规范）","RIGHT","https:\u002F\u002Faction-gmu.oss-cn-guangzhou.aliyuncs.com\u002Fsite\u002Fguideline\u002F7a11422adc924b7da351a1c0b379c602.pdf",5,"RIGHT for Acupuncture","guideline","RIGHT for Acupuncture 将 RIGHT（卫生实践指南报告条目）声明扩展至含针刺推荐的临床实践指南，使指南制定者透明报告证据基础、推荐强度与针刺相关细节。","RIGHT for Acupuncture extends the RIGHT (Reporting Items for practice Guidelines in HealThcare) statement to clinical practice guidelines that include acupuncture recommendations, so guideline developers report the evidence base, recommendation strength and acupuncture specifics transparently.",{"version":64,"nameZh":65,"fileUrlZh":10,"code":66,"fileUrlEn":67,"guidelineId":68,"externalUrl":10,"nameEn":69,"logoUrl":70,"studyType":71,"releaseState":16,"summaryZh":72,"sortNum":58,"summaryEn":73,"status":20},"2.0 版（2020）","ARRIVE 2.0（活体动物实验报告规范）","ARRIVE","https:\u002F\u002Faction-gmu.oss-cn-guangzhou.aliyuncs.com\u002Fsite\u002Fguideline\u002F0e1d32337ab74bffac8ae85be1adb340.pdf",6,"ARRIVE 2.0 (Animal Research: Reporting of In Vivo Experiments)","\u002Fassets\u002Flogo-arrive.png","animal","ARRIVE 2.0（活体动物实验报告规范）规范动物研究的报告，是支撑针刺科学的机制与临床前研究基础。其「核心 10 项」与推荐条目覆盖研究设计、样本量、随机化、盲法、结局指标与统计分析。","ARRIVE 2.0 (Animal Research: Reporting of In Vivo Experiments) governs the reporting of animal studies — the mechanism and pre-clinical research that underpins acupuncture science. The 'Essential 10' plus the recommended set cover study design, sample size, randomisation, blinding, outcome measures and statistics.",100,false,true,"2026-08-11T11:24:27.708618",{"code":4,"msg":5,"data":79,"success":76,"time":116},[80,84,88,92,96,100,104,110],{"catId":13,"catKey":15,"nameEn":81,"sortNum":18,"iconPaths":82,"nameZh":83,"status":20},"RCT","M4 5h16M4 5v14M4 19h16\nM8 15l3-4 2 2 3-5","随机对照试验",{"catId":26,"catKey":28,"nameEn":85,"sortNum":13,"iconPaths":86,"nameZh":87,"status":20},"Protocol","M8 3h6l4 4v14H6V5\nM8 3v4H4\nM9 13h6M9 17h4","试验方案",{"catId":36,"catKey":39,"nameEn":89,"sortNum":26,"iconPaths":90,"nameZh":91,"status":20},"Reviews","M12 3v18\nM5 8l7-5 7 5\nM5 8v8l7 5 7-5V8","系统综述",{"catId":47,"catKey":50,"nameEn":93,"sortNum":36,"iconPaths":94,"nameZh":95,"status":20},"Case report","M7 3h7l4 4v14H6V4\nM14 3v4h4\nM12 11v6M9 14h6","病例报告",{"catId":58,"catKey":60,"nameEn":97,"sortNum":47,"iconPaths":98,"nameZh":99,"status":20},"Guideline","M12 3l8 4v6c0 4.5-3.2 7-8 8-4.8-1-8-3.5-8-8V7z\nM9 12l2 2 4-4","实践指南",{"catId":68,"catKey":71,"nameEn":101,"sortNum":58,"iconPaths":102,"nameZh":103,"status":20},"Animal","M4 20c0-3 2-5 4-5s4 2 4 5\nM15 8c2 0 4 1.5 4 4s-2 4-4 4\nM17 12h.01","动物实验",{"catId":105,"catKey":106,"nameEn":107,"sortNum":68,"iconPaths":108,"nameZh":109,"status":20},7,"nrct","Non-randomised trial","M4 5h16M4 5v14M4 19h16\nM8 16l3-3 2 2 3-4","非随机对照试验",{"catId":111,"catKey":112,"nameEn":113,"sortNum":105,"iconPaths":114,"nameZh":115,"status":20},8,"obs","Observational study","M2 12s3.5-6 10-6 10 6 10 6-3.5 6-10 6-10-6-10-6z\nM12 9.5a2.5 2.5 0 1 0 0 5 2.5 2.5 0 0 0 0-5z","观察性研究","2026-08-11T11:24:27.746884",1786418667477]